Abstract:Background: Pulmonary arterial hypertension (PAH) is a rare but severe and life-threatening condition that primarily affects the pulmonary blood vessels and the right ventricle of the heart. The limited availability of human tissue for research ~most of which represents only end-stage disease~ has led to a reliance on preclinical animal models. However, these models often fail to capture the heterogeneity and complexity of the human condition. Analyzing the molecular signatures in patient plasma provides a unique opportunity to gain insights into PAH pathobiology, explore disease heterogeneity absent in animal models, and identify potential therapeutic targets. Objective: This study aims to characterize the circulating peptides, metabolites, and lipids most relevant to PAH by leveraging unbiased mass spectrometry and advanced computational tools. Building on prior research that identified individual circulating factors, this work seeks to integrate these molecular layers to better understand their interactions and collective contribution to PAH pathobiology. Methods: Peripheral blood samples were collected from 402 patients with PAH and 76 healthy individuals. Various types of molecules in the blood ~ peptides, metabolites, and lipids ~ were measured. Statistical and machine learning methods were used to identify differences between PAH patients and healthy individuals, and further to understand how these molecules might interact with each other. A survival model was also trained to examine the association between the blood molecular signature and patient outcomes. Results: Differential abundance analysis revealed 832 peptides (from 291 proteins), 45 metabolites, and 222 lipids significantly altered in PAH compared to controls. Machine learning-based feature selection identified 11 key molecules, including 2~Hydroxyglutarate, that together achieved a classification accuracy of 98.6% for PAH in a multivariate model tested on a withheld cohort. Latent network discovery uncovered 7 distinct networks, highlighting interacting molecules from pathways ~such as hypoxia, glycolysis, fatty acid metabolism, and complement activation~ that we and others have previously linked to vascular lesions in PAH patients. A survival model incorporating 155 molecular features predicted outcomes in PAH patients with a c-index of 0.762, independent of traditional clinical parameters. This model stratified patients into risk categories consistent with established markers of cardiac function, exercise tolerance, and the REVEAL 2.0 risk score. Conclusion: This study underscores the utility of integrated omics in unraveling PAH pathobiology in human subjects. Our findings highlight the central role of hypoxia signaling pathways interacting with disrupted fatty acid metabolism, complement activation, inflammation, and mitochondrial dysfunction. These interactions, revealed through latent network analysis, emphasize the metabolic and immune dysregulation underlying PAH. Furthermore, many of the molecules identified in the circulation were consistent with pathways enriched in pulmonary vascular lesions, reinforcing their biological relevance. Circulating plasma molecules from these networks demonstrated strong prognostic capabilities, comparable to current clinical risk scores, offering insights into disease progression and potential for future clinical application.

NMR-Based Metabolomic Analysis of Plasma in Patients with Adult Congenital Heart Disease and Associated Pulmonary Arterial Hypertension: A Pilot Study

Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China

Discovery and validation of potential serum biomarkers for pediatric patients with congenital heart diseases by metabolomics.

Metabolomic Identification of Diagnostic Plasma Biomarkers in Humans with Chronic Heart Failure

Protein Biomarkers And Risk Scores In Pulmonary Arterial Hypertension Associated With Ventricular Septal Defect: Integration Of Multi-Omics And Validation

A Pseudo-Targeted Metabolomics for Discovery of Potential Biomarkers of Cardiac Hypertrophy in Rats

Integrated multi-omics analysis of the microbial profile characteristics associated with pulmonary arterial hypertension in congenital heart disease

Identification of potential serum biomarkers for congenital heart disease children with pulmonary arterial hypertension by metabonomics

Identification of metabolic biomarkers in idiopathic pulmonary arterial hypertension using targeted metabolomics and bioinformatics analysis

Metabolomic profiling identifies novel metabolites associated with cardiac dysfunction

Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction

Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline

Altered Lung Microbiome and Metabolome Profile in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease

Identification of candidate biomarkers and molecular networks associated with Pulmonary Arterial Hypertension using machine learning and plasma multi-Omics analysis

Metabolomics Meets Clinics: A Multivariate Analysis of Plasma and Urine Metabolic Signatures in Pulmonary Arterial Hypertension

Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status

Clinical Value of ADMA in Patients with Pulmonary Arterial Hypertension Combination with Congenital Heart Disease

Novel biomarkers identifying hypertrophic cardiomyopathy and its obstructive variant based on targeted amino acid metabolomics

Identification of Metabolic Biomarkers in Patients with Type 2 Diabetic Coronary Heart Diseases Based on Metabolomic Approach

(1)H NMR-Based Analysis of Serum Metabolites in Monocrotaline-Induced Pulmonary Arterial Hypertensive Rats.